Hamano Itsuto, Hatakeyama Shingo, Fujita Takeshi, Murakami Reiichi, Hamaya Tomoko, Togashi Kyo, Suzuki Yuichiro, Yamamoto Hayato, Yoneyama Tohru, Yoneyama Takahiro, Hashimoto Yasuhiro, Narumi Shunji, Tomita Hirofumi, Ohyama Chikara
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Department of Advanced Blood Purification Therapy, Hirosaki, Japan.
Transplant Proc. 2020 Jul-Aug;52(6):1723-1728. doi: 10.1016/j.transproceed.2020.01.157. Epub 2020 May 21.
Kidney transplantation from marginal donors is an important solution for organ shortage problems. In this study, we evaluated the safety and effectiveness of living kidney transplantation from marginal donors at our hospitals.
Between June 2006 and April 2019, 107 patients underwent living kidney transplantation at our hospitals. Marginal donors were defined as those with 1. age >70 years, 2. hypertension, 3. creatinine clearance <80 mL/min, 4. body mass index >30 kg/m, or 5. hemoglobin A1c >6.2%. We retrospectively compared renal function and its chronological changes between marginal and standard donors. We also compared graft survival and recipient renal function between the groups.
Thirty-one (29%) donors were defined as marginal. The primary reason for being defined as marginal was hypertension (74%). The mean age of the marginal donors (62 ± 10 years) was higher than that of standard donors (52 ± 12 years, P < .001). The estimated glomerular filtration rate (eGFR) before and after transplantation was lower in the marginal group, whereas the decline ratio of eGFR was not different between the marginal and standard donors. Five-year graft survival of transplantations from marginal donors (89%) was not significantly inferior to that from standard donors (95%). Meanwhile, recipient eGFR was lower in transplantation from marginal donors than standard donors from 1 month through 5 years after transplantation.
No significant differences were observed between the groups regarding the decline ratios of donor eGFR and graft survival. Thus, transplantation from marginal donors may be a feasible solution for donor shortage problems.
来自边缘供体的肾移植是解决器官短缺问题的重要方法。在本研究中,我们评估了我院进行的来自边缘供体的活体肾移植的安全性和有效性。
2006年6月至2019年4月期间,我院有107例患者接受了活体肾移植。边缘供体定义为符合以下情况之一者:1. 年龄>70岁;2. 患有高血压;3. 肌酐清除率<80 mL/分钟;4. 体重指数>30 kg/m²;或5. 糖化血红蛋白>6.2%。我们回顾性比较了边缘供体和标准供体之间的肾功能及其随时间的变化。我们还比较了两组之间的移植物存活率和受者肾功能。
31名(29%)供体被定义为边缘供体。被定义为边缘供体的主要原因是高血压(74%)。边缘供体的平均年龄(62±10岁)高于标准供体(52±12岁,P<.001)。边缘供体组移植前后的估计肾小球滤过率(eGFR)较低,而边缘供体和标准供体之间eGFR的下降率没有差异。来自边缘供体的移植的5年移植物存活率(89%)并不显著低于来自标准供体的移植(95%)。同时,在移植后1个月至5年期间,来自边缘供体的移植受者的eGFR低于来自标准供体的移植受者。
两组在供体eGFR下降率和移植物存活率方面未观察到显著差异。因此,来自边缘供体的移植可能是解决供体短缺问题的可行方法。